Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan
International Journal of Urology · 2023
DOI: 10.1111/iju.15230 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2023. Verfasst von Ken-Ichi Harada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objectives
The objective of this study was to assess the clinical outcomes following combined treatment with pembrolizumab and axitinib as first‐line therapy for patients with advanced RCC.
Methods
This study retrospectively included 47 consecutive Japanese patients who were diagnosed with advanced RCC and subsequently received pembrolizumab and axitinib between February 2020 and January 2022. Efficacy and safety of this combined therapy in these patients were comprehensively investigated.
Results
The 47 included patients were classified into the following 3 groups by the IMDC system: favorable, 7 (14.9%); intermediate, 24 (51.1%) and poor, 16 (34.0%). Responses to this combined therapy in the 47 patients were as follows: CR, 8 (17.0%); PR, 20 (42.6%); SD, 16 (34.0%) and PD, 3 (6.4%); thus, the ORR was 59.6%. During the observation period, disease progression and death occurred in 19 (40.4%) and 9 (19.1%) patients, respectively, and the median PFS and OS were 18 months and not reached, respectively. Univariate analyses identified the following significant predictors for poor prognostic outcomes: lack of nephrectomy, liver metastasis, bone metastasis, elevated CRP and IMDC poor risk for PFS; and lack of nephrectomy, non‐CCC and elevated CRP for OS. AEs and those corresponding to grade ≥ 3 occurred in all (100%) and 30 (63.8%) patients, respectively.
Conclusions
To our knowledge, this is the first study focusing on real‐world outcomes following pembrolizumab and axitinib for treatment‐naïve advanced Japanese RCC patients, which showed the efficacy and safety of this combined therapy being similar or even superior to those in clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Ken-Ichi Harada, Ryo Sato, Yukari Bando, Yuto Matsushita, Tomoaki Terakawa, Naohiro Fujimoto
Zitieren
APA
Harada, K. I., Sato, R., Bando, Y., Sano, A., Matsushita, Y., Tamura, K., Terakawa, T., Furukawa, J., Fujimoto, N., Fujisawa, M., & Miyake, H. (2023). Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15230
Vancouver
Harada KI, Sato R, Bando Y, Sano A, Matsushita Y, Tamura K, et al. Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan. International Journal of Urology. 2023. doi:10.1111/iju.15230
BibTeX
@article{Harada2023,
author = {Harada, Ken-Ichi and Sato, Ryo and Bando, Yukari and Sano, Asuka and Matsushita, Yuto and Tamura, Keita and Terakawa, Tomoaki and Furukawa, Junya and Fujimoto, Naohiro and Fujisawa, Masato and Miyake, Hideaki},
title = {Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan},
journal = {International Journal of Urology},
year = {2023},
doi = {10.1111/iju.15230}
}
EUVIMED